Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
In part 6 of this Exclusive Interview, John Buse compares the Observe 4D study versus other SGLT2 studies in a conversation with Diabetes in Control Publisher Steve Freed.
John Buse, PhD, MD, is professor, chief of the Division of Endocrinology, and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine.
Transcript of this video segment:
Freed: How did OBSERVE 4D trials or study compare to the results seen in other studies with Canagliflozin and other SGLT2s?
Buse: So, this isn’t the first such study. I mentioned before the clinical trials suggested that Canagliflozin might have a issue with amputation. Ertugliflozin is the other SGLT-2 Inhibitor that has amputation in the label of the drug. The other big clinical trial, the EMPA-REG study with Empagliflozin, didn’t demonstrate any problem with amputation. In this real world evidence space there are about three other studies that have been done before, but this is by far the biggest study that’s been conducted to date and it is specifically in the US population.